The Original Investigation titled 鈥淓stimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018,鈥� published in the March 3, 2020, issue of JAMA,1 was corrected to update data throughout the article. The data changes originated because of corrections to one of the studies used as a source for clinical trial success rates. In addition to updated data throughout the Original Investigation, accompanying Editorials and Letters necessitated corrections to data.2-6 These articles have been corrected online, and a letter of explanation appears in this issue.7
1.Wouters
聽OJ锘�, McKee
聽M锘�, Luyten
聽J锘�. 聽Estimated research and development investment needed to bring a new medicine to market, 2009-2018.聽锘� 听闯础惭础. 2020;323(9):844-853. doi:
2.Deb
聽C锘�, Curfman
聽G锘�. 聽Relentless prescription drug price increases.聽锘� 听闯础惭础. 2020;323(9):826-828. doi:
3.Cutler
聽DM锘�. 聽Are pharmaceutical companies earning too much?聽锘� 听闯础惭础. 2020;323(9):829-830. doi:
4.Dierynck
聽B锘�, Joos
聽P锘�. 聽Research and development costs of new drugs.聽锘� 听闯础惭础. 2020;324(5):516-517. doi:
5.DiMasi
聽JA锘�. 聽Research and development costs of new drugs.聽锘� 听闯础惭础. 2020;324(5):517. doi:
6.Wouters
聽OJ锘�, McKee
聽M锘�, Luyten
聽J锘�. 聽Research and development costs of new drugs鈥攔eply.聽锘� 听闯础惭础. 2020;324(5):518. doi:
7.Wouters
聽OJ锘�, McKee
聽M锘�, Luyten
聽J锘�. 聽Errors in source data for study of drug development costs.聽锘� 听闯础惭础. Published September 20, 2022. doi: